We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Perspective Therapeutics Inc (CATX) Com Stk USD0.001

Sell:$1.58 Buy:$1.61 Change: $0.07 (4.58%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Sell:$1.58
Buy:$1.61
Change: $0.07 (4.58%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Sell:$1.58
Buy:$1.61
Change: $0.07 (4.58%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.

Contact details

Address:
2401 Elliott Avenue, Suite 320
SEATTLE
98121
United States
Telephone:
+1 (509) 3751202
Website:
https://isoray.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CATX
ISIN:
US46489V1044
Market cap:
$921.90 million
Shares in issue:
587.20 million
Sector:
Biotechnology
Exchange:
-
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Lori Woods
    Chairman of the Board
  • Johan Spoor
    Chief Executive Officer, Director
  • Mark Austin
    Co- Principal Financial Officer, Principal Accounting Officer, Vice President - Finance, Corporate Controller, Corporate Secretary
  • Jonathan Hunt
    Chief Financial Officer, Co-Principal Financial Officer
  • Markus Puhlmann
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.